Company news

Aura Biosciences, Inc. news in 2026

Aura Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Aura Biosciences to Participate in Upcoming Investor Conference

November 3, 2026

Aura Biosciences to Participate in Upcoming Investor Conference

September 2, 2026

Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

July 8, 2026

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

June 1, 2026

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)

May 20, 2026

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 19, 2026

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

May 11, 2026

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 5, 2026

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

May 4, 2026

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 4, 2026

Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

May 4, 2026

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

March 29, 2026

Decks in 2026